A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination

  • Brito S
  • Ferreira N
  • Mateus S
  • et al.
N/ACitations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine.

Cite

CITATION STYLE

APA

Brito, S., Ferreira, N., Mateus, S., Bernardo, M., Pinto, B., Lourenço, A., & Grenho, F. (2021). A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination. Cureus. https://doi.org/10.7759/cureus.15035

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free